Bridging Science and Understanding
Apollo Pact illuminates the cutting-edge landscape of psychedelic research. As a 501(c)(3) nonprofit, we educate, by providing policymakers and the public with rigorous, evidence-based insights into the transformative potential of psychedelic science.
PATIENT SAFETY
Psychedelics are illegal in the U.S. Currently, the only legal way to access psychedelic therapies is through clinical trials. You can find if a clinical trial is near you at www.clinicaltrials.gov or email hello@apollopact.org for assistance.
Apollo Pact's founder, Jon Kostas, credits this therapy with curing his alcohol use disorder, after trying all other available treatments. While Apollo Pact works to advance psychedelic science and medical research, we advise against the use of these powerful compounds outside of clinical settings.
1 in 5 American adults experience a mental health issue.
Apollo Pact, Inc. is a medical research and education 501(c)(3) nonprofit. Our mission is to address the mental illness epidemic by relying on science & research.
Our founders were clinical participants in NYU & Johns Hopkins studies. When they realized how well psilocybin medical treatment worked, they knew they had to help others in desperate need access it.
What is psilocybin?
Psilocybin is a compound in psychedelic mushrooms. Research suggests psilocybin-assisted therapy can be more effective than standard treatments for addiction, depression, anxiety, PTSD, and other mental and behavioral health disorders.
Scientific Research
Just like our team members, more and more people are starting to participate in clinical trials. NYU, Johns Hopkins, Yale, and UAB are just a few universities conducting research. Contact us if you or someone you know are interested in participating.
Education & Advocacy
Medical research into psychedelics faces a dual challenge: overcoming stigma surrounding both the compounds themselves and the mental health conditions they may help treat, including depression and addiction. Through objective analysis of clinical trial data, we can demonstrate how psychedelics compare to conventional treatments and medications. By sharing rigorous scientific evidence, we aim to foster an informed public dialogue about psychedelics' potential role in mental healthcare and their capacity to provide meaningful, lasting therapeutic benefits.
“This was the only treatment that worked for me. I haven’t craved a drink since 2015.”
— Jon Kostas on 60 Minutes